deltatrials
Completed NA NCT00000993

A Study of Zidovudine in the Prevention of HIV Infection in Individuals Exposed to the Virus

An Open Protocol for the Use of Zidovudine for Prophylactic Treatment of Individuals After Accidental Massive Exposure to the Human Immunodeficiency Virus (HIV)

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions HIV Infections
Interventions Zidovudine
Updated 5 times since 2017 Last updated: Nov 4, 2016 Primary completion: Jan 31, 2005 Completion: Jan 31, 2005

This NA trial investigates HIV Infections and is currently completed. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Jun 2018 — Jan 2021 [monthly]

    Completed NA

  5. Jan 2017 — Jun 2018 [monthly]

    Completed NA

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Research Triangle Park, United States